Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
Regeneron Pharmaceuticals announced encouraging preliminary Phase 1/2 trial results for ubamatamab, a bispecific antibody targeting MUC16 and CD3, in patients with recurrent low-grade serous ovarian cancer (LGSOC). The highest dose cohort demonstrated a 73% objective response rate and 11-month median progression-free survival in heavily pretreated …